Modality
Multispecific
MOA
Menini
Target
FLT3
Pathway
Neuroinflam
CRCPsoriasis
Development Pipeline
Preclinical
Oct 2017
→ Oct 2030
PreclinicalCurrent
NCT06927543
2,138 pts·Psoriasis
2022-10→2027-06·Recruiting
NCT07442458
2,291 pts·CRC
2017-10→2030-10·Completed
4,429 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-06-101.2y awayInterim· Psoriasis
2030-10-114.5y awayInterim· CRC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2027-06-10 · 1.2y away
Psoriasis
Interim
2030-10-11 · 4.5y away
CRC
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06927543 | Preclinical | Psoriasis | Recruiting | 2138 | SeizFreq |
| NCT07442458 | Preclinical | CRC | Completed | 2291 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 | |
| Motasacituzumab | Olema | NDA/BLA | FLT3 |